Alexandria Capital’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | $400K | Buy |
1,412
+30
| +2% | +$9.83K | 0.04% | 197 |
|
|
2021
Q2 | $479K | Hold |
1,382
| – | – | 0.04% | 186 |
|
|
2021
Q1 | $387K | Hold |
1,382
| – | – | 0.04% | 200 |
|
|
2020
Q4 | $338K | Buy |
1,382
+2
| +0.1% | +$516 | 0.04% | 203 |
|
|
2020
Q3 | $391K | Sell |
1,380
-29
| -2% | -$8.09K | 0.05% | 184 |
|
|
2020
Q2 | $377K | Hold |
1,409
| – | – | 0.05% | 182 |
|
|
2020
Q1 | $446K | Buy |
1,409
+29
| +2% | +$8.8K | 0.07% | 168 |
|
|
2019
Q4 | $409K | Hold |
1,380
| – | – | 0.05% | 191 |
|
|
2019
Q3 | $321K | Sell |
1,380
-6
| -0.4% | -$1.4K | 0.05% | 199 |
|
|
2019
Q2 | $324K | Hold |
1,386
| – | – | 0.05% | 212 |
|
|
2019
Q1 | $327K | Sell |
1,386
-2,810
| -67% | -$885K | 0.05% | 218 |
|
|
2018
Q4 | $1.26M | Sell |
4,196
-40
| -0.9% | -$12.8K | 0.21% | 124 |
|
|
2018
Q3 | $1.5M | Hold |
4,236
| – | – | 0.22% | 114 |
|
|
2018
Q2 | $1.23M | Sell |
4,236
-120
| -3% | -$33.7K | 0.18% | 121 |
|
|
2018
Q1 | $1.19M | Sell |
4,356
-120
| -3% | -$37.2K | 0.18% | 122 |
|
|
2017
Q4 | $1.43M | Buy |
4,476
+4,465
| +40,591% | +$1.43M | 0.21% | 116 |
|
|
2017
Q3 | $3K | Sell |
11
-13
| -54% | -$3.85K | ﹤0.01% | 479 |
|
|
2017
Q2 | $7K | Hold |
24
| – | – | ﹤0.01% | 452 |
|
|
2017
Q1 | $7K | Hold |
24
| – | – | ﹤0.01% | 448 |
|
|
2016
Q4 | $7K | Hold |
24
| – | – | ﹤0.01% | 445 |
|
|
2016
Q3 | $8K | Sell |
24
-11
| -31% | -$3.26K | ﹤0.01% | 436 |
|
|
2016
Q2 | $8K | Buy |
35
+8
| +30% | +$2.11K | ﹤0.01% | 435 |
|
|
2016
Q1 | $7K | Hold |
27
| – | – | ﹤0.01% | 458 |
|
|
2015
Q4 | $8K | Sell |
27
-3
| -10% | -$862 | ﹤0.01% | 478 |
|
|
2015
Q3 | $9K | Buy |
30
+5
| +20% | +$1.65K | ﹤0.01% | 417 |
|
|
2015
Q2 | $10K | Sell |
25
-2
| -7% | -$803 | ﹤0.01% | 418 |
|
|
2015
Q1 | $11K | Sell |
27
-2
| -7% | -$788 | ﹤0.01% | 375 |
|
|
2014
Q4 | $10K | Sell |
29
-3
| -9% | -$971 | ﹤0.01% | 359 |
|
|
2014
Q3 | $11K | Buy |
32
+4
| +14% | +$1.32K | ﹤0.01% | 333 |
|
|
2014
Q2 | $9K | Buy |
28
+8
| +40% | +$2.41K | ﹤0.01% | 363 |
|
|
2014
Q1 | $6K | Hold |
20
| – | – | ﹤0.01% | 422 |
|
|
2013
Q4 | $6K | Hold |
20
| – | – | ﹤0.01% | 420 |
|
|
2013
Q3 | $5K | Buy |
20
+1
| +5% | +$224 | ﹤0.01% | 449 |
|
|
2013
Q2 | $4K | Buy |
+19
| New | +$4.06K | ﹤0.01% | 509 |
|
Other funds holding BIIB
Alexandria Capital's BIIB Position: Q3 2021 in Review
Alexandria Capital increased its Biogen (BIIB) stake by 2.2% in Q3 2021, buying an estimated $9.83K and bringing the position to 1,412 shares worth $400K. The position accounts for 0.04% of the portfolio, ranked #197.
Alexandria Capital first reported a position in BIIB in Q2 2013 and has held it in 34 quarters since. The position peaked at $1.5M in Q3 2018. 1,040 funds tracked by Wall St. Rank hold BIIB as of Q3 2021.
- Alexandria Capital held 1,412 shares of Biogen worth $400K as of Q3 2021.
- Alexandria Capital bought 30 Biogen shares in Q3 2021, an estimated $9.83K.
- Biogen made up 0.04% of Alexandria Capital's portfolio in Q3 2021, its #197 holding.
- Alexandria Capital first reported a position in Biogen in Q2 2013 and has held it in 34 quarters since.
- Alexandria Capital's Biogen position peaked at $1.5M in Q3 2018.
- 1,040 funds tracked by Wall St. Rank held Biogen as of Q3 2021.
Based on Alexandria Capital's 13F filing for Q3 2021, filed 2 Dec 2021.